INVEX Therapeutics Ltd Cash Flow Conversion Efficiency
INVEX Therapeutics Ltd cash flow conversion efficiency. Based on the latest financial reports, INVEX Therapeutics Ltd (IXC) has a cash flow conversion efficiency ratio of -0.171x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-779.73K ≈ $-551.71K USD) by net assets (AU$4.55 Million ≈ $3.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of INVEX Therapeutics Ltd (2019–2025)
Cash flow conversion efficiency of INVEX Therapeutics Ltd from 2019 to 2025. This chart illustrates how INVEX Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View IXC stock price and chart for real-time trading data and today's change.
INVEX Therapeutics Ltd Cash Flow Conversion Ratio Explained
INVEX Therapeutics Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
INVEX Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of INVEX Therapeutics Ltd ranked by their cash flow conversion efficiency. Also see INVEX Therapeutics Ltd (IXC) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
iMetal Resources Inc
V:IMR
|
-0.024x |
|
Stenocare AS
CO:STENO
|
0.180x |
|
Island Concepts Indonesia Tbk
JK:ICON
|
-0.049x |
|
YOLO GROUP S.P.A. O.N.
F:X2Y
|
N/A |
|
Noronex Ltd
AU:NRX
|
-2.126x |
|
Xpon Technologies Group Ltd
AU:XPN
|
-1.594x |
|
Pulse Oil Corp
V:PUL
|
0.019x |
|
Gelteq Limited Ordinary Shares
NASDAQ:GELS
|
-0.021x |
Annual Cash Flow Conversion Efficiency for INVEX Therapeutics Ltd (2019–2025)
The table below shows the annual cash flow conversion efficiency of INVEX Therapeutics Ltd from 2019 to 2025. Review financial flexibility index of INVEX Therapeutics Ltd to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$5.25 Million ≈ $3.71 Million |
AU$-652.57K ≈ $-461.74K |
-0.124x | +71.05% |
| 2024-06-30 | AU$5.69 Million ≈ $4.02 Million |
AU$-2.44 Million ≈ $-1.73 Million |
-0.430x | -32.80% |
| 2023-06-30 | AU$21.23 Million ≈ $15.02 Million |
AU$-6.87 Million ≈ $-4.86 Million |
-0.324x | -172.89% |
| 2022-06-30 | AU$28.48 Million ≈ $20.15 Million |
AU$-3.38 Million ≈ $-2.39 Million |
-0.119x | -126.62% |
| 2021-06-30 | AU$32.08 Million ≈ $22.70 Million |
AU$-1.68 Million ≈ $-1.19 Million |
-0.052x | +20.38% |
| 2020-06-30 | AU$24.40 Million ≈ $17.27 Million |
AU$-1.60 Million ≈ $-1.13 Million |
-0.066x | -226.59% |
| 2019-06-30 | AU$11.44 Million ≈ $8.09 Million |
AU$-230.13K ≈ $-162.83K |
-0.020x | -- |
About INVEX Therapeutics Ltd
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of efficacious treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has comple… Read more